Keeping Track: Tecentriq, Cyramza Celebrate ASCO With New Indications; Brilinta Moves Earlier In Coronary Artery Disease

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Keeping Track Feature image

With the annual American Society of Clinical Oncology meeting reduced to virtual sessions and other events commanding the country’s attention, oncology hasn’t been dominating the newsflow as it usually does in late spring. The US Food and Drug Administration’s approval of new indications for Genentech Inc.’s Tecentriq (atezolizumab) and Cyramza (ramucirumab) gave Roche and Eli Lilly & Co., respectively, something to talk about.

AstraZeneca PLC trumpeted FDA’s approval of a new indication for its anticoagulant Brilinta (ticagrelor) to reduce the risk of...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers